ORIC vs. PHAT, IPHA, ARQT, KPTI, BTAI, BHC, MRVI, RYTM, DCPH, and ARVN
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Innate Pharma (IPHA), Arcutis Biotherapeutics (ARQT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), and Arvinas (ARVN). These companies are all part of the "medical" sector.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
ORIC Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 122.47%. Phathom Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 133.55%. Given Phathom Pharmaceuticals' higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than ORIC Pharmaceuticals.
Phathom Pharmaceuticals' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.
Phathom Pharmaceuticals received 24 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 68.27% of users gave Phathom Pharmaceuticals an outperform vote while only 66.20% of users gave ORIC Pharmaceuticals an outperform vote.
ORIC Pharmaceuticals has higher earnings, but lower revenue than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ORIC Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
In the previous week, ORIC Pharmaceuticals and ORIC Pharmaceuticals both had 7 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.69 beat ORIC Pharmaceuticals' score of 0.67 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.
95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Phathom Pharmaceuticals beats ORIC Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
